Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from University of Texas in breast cancer provides new insights
June 18th, 2009
According to recent research published in the American Journal of Surgical Pathology, "HER2 is an important predictive marker for response to trastuzumab and lapatinib in breast cancer. It is also a powerful prognostic marker in node-positive patients." "Although standardized assays are used to help select patients for anti-HER2 therapy, there arc no standardized criteria for assessing HER2 as a prognostic marker. Recent data Using quantitative image analysis suggest that both high and low HER2 expression are associated with poor clinical outcome. Using the immunohistochemical scoring criteria currently recommended by the College of American Pathologists and...
Source: Women's Health Weekly (2009-06-18)
|
